Terminal cancer patients do not receive appropriate radiation therapy

	Tweet

A new analysis has found that a considerable proportion of patients with end-stage or terminal cancer do not benefit from palliative radiation therapy (radiotherapy) despite spending most of their remaining life undergoing treatments. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that greater efforts are needed to tailor appropriately palliative radiotherapy to patients with end-stage cancer.

Palliative radiotherapy for end-stage cancer patients is intended to control cancer-related pain and other symptoms and to help patients maintain a good quality of life when long-term cancer control is not possible. By reducing the number of cancer cells, palliative radiotherapy can ease pain, stop bleeding, and relieve pressure, even when the cancer cannot be controlled. However, for many patients, the treatments are not effective. In addition, if patients are close to death, they may wish to stop treatments if they would like to die at home.

To investigate the adequacy of palliative radiotherapy in end-stage cancer patients, Stephan Gripp, MD, of the University Hospital Duesseldorf in Germany and colleagues evaluated the treatment of patients who were referred for palliative radiotherapy at their hospital from December 2003 to July 2004 and who died within 30 days. The investigators identified 33 such patients. 

Radiotherapy was delivered to 91 percent of patients. Half of the patients spent more than 60 percent of their remaining lifespan on radiotherapy, and in only 58 percent of patients was radiotherapy completed. Many physicians overestimated the length of time their patients would survive. Among this group who died within one month, about one in five physicians predicted more than six months survival. In addition, progressive complaints were noted in 52 percent of patients, and palliation or pain reduction was reported by only 26 percent of patients.

The authors concluded that radiotherapy was not appropriately customized to these cancer patients, many of whom did not benefit despite spending most of their remaining life on therapy. Excessive radiotherapy in end-stage cancer patients may reflect overoptimistic prognoses and unrealistic concerns about radiation damage.

“Radiation oncologists have fallen short in accurately determining the life span of terminally ill cancer patients. This has resulted in unduly prolonged radiation therapy regimens that often go uncompleted due to death or withdrawal from treatment,” said Dr. Gripp. He added that physicians need better methods for estimating how long their end-stage cancer patients will live. He also recommended that they use shorter-duration radiation schedules for palliative radiotherapy.

###

Article: “Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: reality or myth?” Stephan Gripp, Sibylle Mjartan, Edwin Boelke, and Reinhardt Willers. CANCER; Published Online: April 12, 2010 (DOI: 10.1002/cncr. 25112).

Author Contact: To arrange an interview with Dr. Gripp, please contact Susanne Dopheide of the Heinrich-Heine-Universität Press Office:+49 211 81-04173 or

---
Contact: Claire Greenwell

404-417-5883
American Cancer Society

RELATED STORIES:
New measurement technique will help in fight against cancer   Cancer: The good news   10 Ways to Reduce Cancer Risk   Yttrium-90 to control hepatocarcinoma   Errors in cancer diagnosis common, often harmful   Helping to Identify Small Tumors Early   Men with BRCA2 gene mutation have higher cancer risk   How cancer cells can escape normal growth controls   Cancer risk slightly higher in IVF kids: study   Scientists detect cancer genes with new algorithm   GW wins US okay for pivotal cannabis drug study   Improving Cancer Diagnosis   NCCN Cancer Guidelines Focus on Adolescent, Young Adult Needs   Reversing cell division has implications for the treatment of cancer   Fruit research yields way to curb cancer   Smoking and hepatitis C up risk of lymphoma   Cancer will kill 13.2 million a year by 2030: U.N.   Medicare modernization act did not change chemotherapy as feared   How cancer cells loose their (Circadian) rhythm   $1 million of mesothelioma research funding   Researchers Discover New Genes That Fuse in Cancer   Targeting key proteins of carcinogenesis

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]